Blog

Memory loss has long been considered the defining hallmark of Alzheimer’s disease. But there is more to the disease than misplaced keys, forgotten names, and other memory lapses. Reducing Alzheimer’s to memory alone oversimplifies a disease that affects multiple aspects of thinking, behavior, and daily functioning.

As researchers develop more sophisticated biomarkers, disease-modifying therapies, and prevention strategies, they also recognize that the tools used to measure cognition must evolve. Alzheimer’s affects far more than memory, and understanding the disease requires assessing the full range of cognitive and behavioral changes that patients experience.

This theme emerged during the third episode of “The Progress Profile: Alzheimer’s Research in Focus,” in which Maria Carrillo, Ph.D., chief science officer and medical affairs lead at the Alzheimer’s Association, joined moderator Dr. John Harrison to discuss why the field is broadening its view of cognitive decline.

Women account for almost two-thirds of people living with Alzheimer's disease. For years, the higher prevalence was largely attributed to the fact that women tend to live longer than men. But during a recent episode of The Progress Profile: Alzheimer's Research in Focus podcast, Phyllis Ferrell, DrPH, MBA, innovator, investor, and incubator for brain health and longevity, argued that explanation no longer tells the whole story.

In a conversation about the future of Alzheimer's research, moderator Dr. John Harrison, engaged Ferrell in conversation about the ways advances in biomarkers, cognitive testing, and precision medicine are revealing important biological differences between men and women. Their discussion highlighted an emerging area of research that could reshape everything from clinical trial design to early diagnosis and treatment.

“We're learning something that we've known in other disease states,” Ferrell said. “Women's brains are not just little men's brains.”

Alzheimer’s disease has long been studied as a distinct condition with its own symptoms, progression, and treatment strategies. But researchers are increasingly looking beyond the diagnosis and asking bigger questions about the biology that drives neurodegeneration.

That broader perspective is the focus of the first episode in the Pearson podcast series, “The Progress Profile: Alzheimer’s Research in Focus.”

In this episode, Lon Schneider, M.D., director of the California Alzheimer’s Disease Center at the University of Southern California; and Stephen Salloway, M.D., founding director of the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, join moderator John Harrison, Ph.D., associate professor of VU University Medical Center, to discuss the remarkable progress in Alzheimer’s research, the challenges that remain, and how advances in biomarkers, measurement, and early detection are changing the way scientists think about brain health.

Throughout the conversation, one message became clear: Understanding disease biology is just as important as understanding symptoms. Advances in Alzheimer’s research are creating new ways to identify pathology earlier, measure change with more accuracy, and develop interventions increasingly tailored to individual patients.

Rather than focusing only on where a patient is today, the conversation looked at where research is headed and how deeper biological understanding could transform the field.

What’s Ahead in season two of the podcast series, “The Progress Profile: Alzheimer’s Research in Focus.”

For most people, video games are a form of entertainment. For Rhoda Au, Ph.D., professor at Boston University, video games represent something far more profound: a potential window into the human brain.

Clinical Outcome Assessments (COAs) are essential for translating patient experiences into meaningful trial data, but they also bring complexity that creates friction.

A new research report, “Unlocking the Power of COAs in Clinical Research,” found that early and strategic planning can help address the top three COA friction points: licensing, translations, and rater training.

In this blog, we share findings on where the greatest opportunities lie — and why planning earlier and partnering smarter are keys to stronger trial execution.

When Dr. Miia Kivipelto launched the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability, better known as the FINGER trial, in 2009, the field of dementia prevention was much different.

“At that time, [the focus was only on] high age and genetic factors,” Kivipelto said. “Now we know that 45% of these risk factors are there throughout the whole life course and that’s why we say that it’s never too early to … prevent dementia.”

Kivipelto, a Finnish neuroscientist and professor who specializes in dementia and Alzheimer’s disease, joined John Harrison, Ph.D., CPsychol, CSci, AFBPsS, an associate professor at Alzheimercentrum, AUmc, Amsterdam, for the Pearson-sponsored podcast series, “The Progress Profile: Alzheimer’s Research in Focus,” to share insights into her research.

What decades of research reveal about brain health, early detection, and the future of dementia care